HLB shares showed strength in Friday's after-hours trading, and investors are on high alert ahead of the regular session on Monday, November 2. Attention is focused on HLB's stock price on the first trading day of November, as the schedule for the U.S. Food and Drug Administration's (FDA) re-review of the new drug approval also coincides.

FDA Resubmission Review: The 'Class 1 vs Class 2' Crossroads

The FDA reviews new drug approval resubmission materials and classifies them as either Class 1 or Class 2. Generally, a two-month review goal applies to Class 1, while a six-month goal applies to Class 2. Therefore, depending on which type it is classified as, differences may arise in the future review schedule. However, the determination of the review type does not confirm whether final approval will be granted.

Will After-Market Strength Carry Over to Monday's Regular Session?

Another point of interest is whether HLB's strength seen in Friday's after-market will continue into Monday's regular session. The after-market differs from the regular session in terms of participants and liquidity, which can lead to larger price swings. Even though the stock rose in Friday's after-hours trading, it cannot be assumed that Monday's opening price and intraday movement will follow the same direction.

In particular, HLB is a stock where investors' attention is focused on FDA approval-related schedules and news about U.S. market listing and commercialization. Depending on whether new official announcements are made, stock price volatility could expand.

Key Points to Watch in the November 2 Trading

In Monday's trading on November 2, key items to watch include: the difference between Friday's after-market price and the regular session's opening price, changes in trading volume, and the buying and selling trends of foreign and institutional investors. It is also necessary to check whether there will be additional announcements regarding Eleva's Reflupto pricing schedule and the FDA review classification.

[Stock investment carries the risk of principal loss. Careful verification of information is required. This publication bears no legal or financial responsibility. This article was written with partial assistance from AI.]